Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
SELLAS Life Sciences (SLS) is trading at $11.79 with a market cap near $2.2B and a heavily shorted float. The market is positioned for a binary clinical readout for SLS009 in acute myeloid leukemia that could produce a dramatic re-rating. This trade idea outlines a long-biased, event-driven plan: entry at $11.79, stop $7.50, target $22.00, with a l…
Nvidia's position as the default AI infrastructure provider has widened beyond a single product concentration argument. With a $5.51 trillion market cap, an improving revenue mix (networking, CPUs, software), and concrete infrastructure commitments from Japanese industrial giants, the old bear case that centers on a one‑product concentration is inc…
Clearmind Medicine announced that its Independent Data and Safety Monitoring Board has approved advancing the Phase I/II clinical trial of CMND-100 to parts B and C, marking the first evaluation of the drug in patients with moderate to severe Alcohol Use Disorder (AUD). This approval follows the successful achievement of the primary safety endpoint…
IREN Limited successfully delivered its first AI cloud deployment, Horizon 1, to Microsoft under a $9.7 billion cloud services contract, achieving NVIDIA Exemplar Cloud status after testing its NVIDIA GB300 NVL72 system. The company aims for significant AI cloud capacity expansion in 2026 and 2027, demonstrating strong execution capabilities and ve…
Advanced Flower Capital Inc. reported its financial results for Q2 2026, highlighting a GAAP net investment income of $3.5 million ($0.15 per share) and an increase in net asset value (NAV) per share to $8.25. The company also repurchased 839,406 shares under its share repurchase program, generating NAV accretion. AFC's investment portfolio grew to…
Intuitive Machines, Inc. announced strong second quarter 2026 financial results with record revenue of $206 million, driven by spacecraft production and multiple contracts across commercial, civil, and national security space sectors. The company expanded its backlog to $1.8 billion, including new contracts for commercial satellites, NASA lunar mis…
Cerenome, Inc., a U.S. CNS oncology company, announced a significant in-network agreement with Health Care Service Corporation (HCSC) to provide its CNSide® cerebrospinal fluid tumor cell enumeration assay. This expands Cerenome's contracted commercial and Medicare Advantage coverage to over 153 million covered lives, surpassing their 2026 year-end…
FitLife Brands, Inc. reported a 65% increase in total revenue to $26.5 million in Q2 2026, driven primarily by the acquisition of Irwin Naturals. Wholesale revenue surged 156%, with Irwin contributing $10.7 million. Despite a decline in Legacy FitLife revenue, overall net income rose 12% to $2.0 million and adjusted EBITDA was up 10%. The company r…
MiNK Therapeutics reported second quarter 2026 financial results and clinical progress on its lead product, agenT-797, which is an off-the-shelf allogeneic invariant natural killer T cell therapy. The company initiated dosing in a randomized Phase 2 clinical trial (C-1300-02) for acute lung injury and ARDS in Ukraine, achieving Day 28 survival and …
Cabaletta Bio reported Q2 2026 financial results and updated progress on its lead CAR T cell therapy, rese-cel, designed to treat autoimmune diseases. Key milestones include on-track registrational RESET-Myositis data expected mid-2027 to support a 2H27 BLA submission, initiation of registrational RESET-SSc study in Q4 2026, and expansion of PC-fre…
Abeona Therapeutics reported strong Q2 2026 financial results highlighted by a 31% sequential increase in net revenue from their gene therapy product ZEVASKYN to $11.4 million. The company expanded its qualified treatment center (QTC) network nationwide and secured New Technology Add-On Payment (NTAP) status from CMS, facilitating Medicare reimburs…
NervGen reported Q2 2026 financial results and business updates, highlighting the upcoming start of site activation and participant screening for its pivotal Phase 3 RESTORE clinical trial targeting chronic spinal cord injury with NVG-291. The company enhanced its leadership team and secured $61.1 million USD in cash, affirming funding sufficiency …
Reborn Coffee Inc. has entered into a $20 million per year agricultural products supply agreement with The Mighty Oak Inc., converting existing supply volume to establish a solid revenue base and improve profitability. The deal enables Reborn Coffee to expand its supply chain operations in North America by leveraging AI demand forecasting and in-ho…
Collegium Pharmaceutical has initiated an accelerated share repurchase (ASR) agreement to buy back $50 million of its common stock as part of a previously authorized $150 million share repurchase program. The transaction, facilitated by Jefferies LLC, reflects management's confidence in the company's growth prospects, particularly in its ADHD portf…
Indonesia Energy Corporation (NYSE American: INDO) has reported that its K-29 well in the Kruh Block on Sumatra continues to drill ahead on schedule, reaching over 2,500 feet with a targeted depth of 3,400 feet. Following K-29, drilling at the WK-5 wellsite will commence. The company also announced a presentation at the EnerCom Energy Investment Co…
Creative Realities, Inc. announced strong second quarter fiscal 2026 results, showcasing significant revenue growth to $21.5 million from $13.0 million a year prior, driven by the acquisition of Cineplex Digital Media and increased service revenue. The company secured a major contract with a national grocery chain to deploy a Retail Media Network, …
GDS Holdings Limited announced solid financial results for Q2 2026, with a 6.5% year-over-year increase in net revenue to RMB3,088 million and a net income of RMB837.6 million, a significant improvement from a net loss in the prior year. The company saw growth in total area committed, area utilized, and data centers in service, driven by increased …
CorMedix Therapeutics reported strong financial results for Q2 2026, showing consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, driven by product sales including DefenCath and the acquired Melinta portfolio. The company maintained full-year 2026 revenue guidance and raised its adjusted EBITDA …
Ascendis Pharma reported a remarkable 105% year-over-year increase in Q2 2026 product revenue to €315 million, driven primarily by strong patient demand for its TransCon products YORVIPATH, SKYTROFA, and newly launched YUVIWEL. The company achieved profitability with an operating profit of €220 million and net profit of €207 million. Key clinical a…
Gold.com (GOLD) looks like a practical way to trade a sustained gold bull without owning futures. With miners consolidating assets and fewer large corporate distractions, bullion distribution volumes should remain robust. GOLD is trading at $44.68, near a mid-cycle valuation (P/E ~16, EV ~$1.87B) and producing strong free cash flow. This trade idea…
UTStarcom Holdings Corp. announced a change in its finance leadership. CFO Dan Xie will step down from his role effective August 21, 2026, moving to Vice President overseeing India and Japan operations. Ying Kang joins as Assistant Vice President of Finance and will take full control of the finance department starting August 21, 2026. The changes w…
The Antwerp World Diamond Centre (AWDC) has denied any connection between a luxury ring presented as a diplomatic gift and a subsequent U.S. tariff exemption for European natural diamonds, after two Democratic senators sought answers and warned of possible legal issues under U.S. federal bribery law.
Meta’s Family of Apps continues to generate robust cash flow and attractive returns on equity, trading at a mid-20s P/E while producing roughly $41B of free cash flow. The main risk is elevated capex and spending cadence tied to AI infrastructure and Reality Labs. This trade aims to capture upside from a slower-than-feared ad slowdown and multiple …
Liminatus Pharma, a biopharmaceutical company, announced its stock was transferred to the Nasdaq Capital Market and that it received an extension until September 3, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company intends to take necessary actions to comply while continuing its clinical development in cancer thera…
Cellectar Biosciences reported strong second quarter 2026 results, highlighted by initiation of site activation for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström Macroglobulinemia, planned NDA submission under FDA's Accelerated Approval Program in mid-2027, positive Phase 2b CLOVER WaM data, and ongoing Phase 1b trial enrollment…
